Physician

Endocrinology

Dr. Bruce H. Mitlak, MD

Bruce Mitlak practices Endocrinology. Bruce Mitlak is also published. He has 59 publications published. The lastest publication: "Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women.'

Publications

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.
FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
The Effect of Discontinuing Treatment with Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women with Low Bone Mineral Density.
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Effect of Raloxifene on all-cause mortality.
Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.
Osteosarcoma and teriparatide?
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Grou...
Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
Pharmacogenomics in endocrinology.
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.
Adherence to treatment of osteoporosis: a need for study.
Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Update in endocrinology.
Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics ...
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Et...
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Raloxifene and risk for stroke based on the framingham stroke risk score.
Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting.
Critical issues in translational and clinical research for the study of new technologies to enhance bone repair.
Selective estrogen receptor modulators: a look ahead.
Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women.
Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators.
Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
The effect of systemically administered PDGF-BB on the rodent skeleton.
Diagnosis and treatment of osteoporosis.
Accuracy, precision, and utility of spine and whole-skeleton mineral measurements by DXA in rats.
A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia.
Parathyroid function in normocalcemic renal transplant recipients: evaluation by calcium infusion.
Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats.
Asymptomatic primary hyperparathyroidism.
Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas.
Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats.
Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture.
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal wom...
Beyond hip: importance of other nonspinal fractures.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, rand...
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outco...
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteo...
Parathyroid hormone as a therapeutic agent.
Comments on Initial experience with teriparatide in the United States.
Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
Long-term raloxifene for postmenopausal osteoporosis.

Schools

Univ Of Ct Sch Of Med

Doctors Specialties

Endocrinology

Accepted Insurances

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. James E. Meacham, MD This Doctor is OpenDoctor Recommended.
	Dr. George T. Lukemeyer, MD This Doctor is OpenDoctor Recommended.
	Dr. Cary N. Mariash, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Melissa K. Cavaghan, MD This Doctor is OpenDoctor Recommended.